Resource Capital Corp. Prices Public Offering of Common

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Resource Capital Corp. Prices Public Offering of Common Stock

NEW YORK, NY--(Marketwired - Apr 10, 2013) - Resource Capital Corp. ( NYSE : RSO ) (the "Company") announced today the pricing of its underwritten offering of 16,250,000 shares of its common stock at a public offering price of $6.33 per share. The Company has granted the underwriters a 30-day option to purchase up to 2,437,500 additional shares of the Company's common stock. The offering is expected to close on April 15, 2013.

Deutsche Bank Securities and J.P. Morgan are acting as the joint book-running managers of the offering.

The Company intends to use the net proceeds from the offering for general corporate purposes.

A registration statement relating to the offered securities has been declared effective by the Securities and Exchange Commission ("SEC"). The offering is being made only by means of a prospectus supplement and accompanying base prospectus. Copies of the preliminary prospectus supplement and the related prospectus for the proposed offering, when available, may be obtained by contacting: Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, by calling (800) 503-4611, or by emailing prospectus.cpdg@db.com ; or by contacting J.P. Morgan Securities LLC, via telephone at (866) 803-9204 or by mail at Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the shares, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Resource Capital Corp.

RSO is a diversified real estate finance company that is organized and conducts its operations to qualify as a REIT for federal income tax purposes. RSO's investment strategy focuses on CRE assets, and, to a lesser extent, commercial finance assets and other investments. RSO invests in the following asset classes: CRE-related assets such as commercial real estate property, whole loans, A-notes, B-notes, mezzanine loans, CMBS and investments in real estate joint ventures as well as commercial finance assets such as bank loans, lease receivables, other asset-backed securities, corporate bonds, trust preferred securities, structured note investments, and private equity investments principally issued by financial institutions.

RSO is externally managed by Resource Capital Manager, Inc., an indirect wholly owned subsidiary of Resource America, Inc. ( NASDAQ : REXI ), a specialized asset management company that uses industry specific expertise to generate and administer investment opportunities for its own account and for outside investors in the real estate, commercial finance and financial fund management sectors.

This press release includes statements that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that are difficult to predict and many of which are beyond management's control. Factors that can affect future results are discussed in the documents filed by Resource Capital Corp. from time to time with the Securities and Exchange Commission. Resource Capital Corp. undertakes no obligation to update or revise any forward-looking statement to reflect new or changing information or events.

Contact: Resource Capital Corp. Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 22

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 27

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Expands Tax Advisory Team with New Experts

Updated Category News Views 199

FTI Consulting Strengthens Tax Advisory Team FTI Consulting, Inc. (NYSE: FCN) has announced the strategic enhancement of its Tax Advisory team within the EMEA region through the recruitment of two highly experienced professionals. This move reflects the company's commitment to providing top-tier advisory services amidst the complexities of the global tax environment. New...

Continue Reading
Cingulate Inc. Unveils Q1 Financial Highlights and Future Plans

Updated Category News Views 148

Cingulate Inc. Reports First Quarter Financial Results Cingulate Inc. (NASDAQ: CING), a biopharmaceutical entity known for its innovative Precision Timed Release™ (PTR™) drug delivery technology, has recently unveiled its financial results for the first quarter. The report sheds light on several important developments concerning their lead assets for ADHD and anxiety....

Continue Reading
Innovative Partnership Propels Sen-Jam Pharmaceutical's Future

Updated Category News Views 106

Strategic Partnership to Enhance Phase 3 Trial for SJP-001 In a significant move, Sen-Jam Pharmaceutical has announced a promising partnership with TASK Clinical, a renowned global contract research organization (CRO), aimed at funding two-thirds of the upcoming Phase 3 clinical trial for its lead candidate, SJP-001. This equity-backed collaboration is not only innovative...

Continue Reading
Exploring the Future of Solar Energy: Insights from EnergySage

Updated Category News Views 231

EnergySage's Solar & Storage Marketplace Report Highlights EnergySage, a trusted name in solar market analysis, has released its latest report, which delves into the current dynamics of the solar and storage marketplace. This comprehensive analysis examines trends that are influencing the future of the industry, particularly in light of recent policy shifts. Residential...

Continue Reading
Investors' Rights: Explore Possible Violations for SCS, HLVX and Others

Updated Category News Views 166

Investigation into Potential Shareholder Violations Halper Sadeh LLC, a well-known law firm advocating for investor rights, is currently investigating several companies due to potential breaches of federal securities laws and fiduciary duties to their shareholders. Steelcase Inc. (SCS) Steelcase Inc. is reportedly undergoing a transaction involving the sale to HNI...

Continue Reading